The Royal Melbourne Hospital, located in Parkville, Victoria, an inner suburb of Melbourne, is one of Australia's leading public hospitals. It is a major teaching hospital for tertiary health care with a reputation in clinical research.

There are 571 beds in Royal Melbourne Hospital.

During the past decade, Royal Melbourne Hospital conducted 279 clinical trials. In the 10-year time frame, 279 clinical trials started and 142 clinical trials were completed, i.e. on average, 50.9% percent of trials that started reached the finish line to date. In the past 5 years, 126 clinical trials started and 87 clinical trials were completed. i.e. 69% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Royal Melbourne Hospital" #1 sponsor was "Melbourne Health" with 32 trials, followed by "Pfizer" with 30 trials sponsored, "Australian and New Zealand Intensive Care Research Centre" with 13 trials sponsored, "Gilead Sciences" with 12 trials sponsored and "The George Institute" with 12 trials sponsored. Other sponsors include 363 different institutions and companies that sponsored additional 207 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Royal Melbourne Hospital" #1 collaborator was "National Health and Medical Research Council, Australia" with 22 trials as a collaborator, "Melbourne Health" with 11 trials as a collaborator, "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 8 trials as a collaborator, "Monash University" with 7 trials as a collaborator and "The Florey Institute of Neuroscience and Mental Health" with 6 trials as a collaborator. Other collaborators include 303 different institutions and companies that were collaborators in the rest 239 trials.

According to Clinical.Site data, the most researched conditions in "Royal Melbourne Hospital" are "Crohn's Disease" (17 trials), "Ulcerative Colitis" (12 trials), "Fabry Disease" (11 trials), "Stroke" (9 trials) and "Alzheimer's Disease" (8 trials). Many other conditions were trialed in "Royal Melbourne Hospital" in a lesser frequency.

Most popular intervention types in "Royal Melbourne Hospital" are "Drug" (361 trials), "Other" (47 trials), "Biological" (44 trials), "Device" (29 trials) and "Procedure" (24 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (129 trials), "Tenecteplase" (6 trials), "Guselkumab" (5 trials), "Placebo oral capsule" (5 trials) and "Ribavirin" (5 trials). Other intervention names were less common.

The vast majority of trials in "Royal Melbourne Hospital" are 440 trials for "All" genders, 15 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are 132 active trials in "Royal Melbourne Hospital". 3 are not yet recruiting, 75 are recruiting, 47 are Active, not recruiting, and 7 are Enrolling by invitation. In total, there were 268 completed trials in Royal Melbourne Hospital, undefined suspended trials, and 51 terminated clinical trials to date.

Out of the total trials that were conducted in Royal Melbourne Hospital, 47 "Phase 1" clinical trials were conducted, 146 "Phase 2" clinical trials and 194 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 28 trials, and there were also 48 trials that are defined as “Not Applicable".

Royal Melbourne Hospital has several departments that took part in Clinical trials: "Royal Melbourne Hospital; Hematology and Medical Oncology" - 8 trials, "Royal Melbourne Hospital; Department of Neurology" - 4 trials, "Royal Melbourne Hospital; Department of Colorectal Medicine and Genetics" - 3 trials, "Royal Melbourne Hospital, Department of Respiratory Medicine" - 2 trials, "Intensive Care Unit Royal Melbourne Hospital Grattan Street" - 2 trials